Global Myocardial Infarction Market Insights Forecasts to 2032

• The Global Myocardial Infarction Market Size was valued at USD 1.9 Billion in 2022.
• The market is growing at a CAGR of 6.8% from 2022 to 2032.
• The worldwide Myocardial Infarction Market size is expected to reach USD 3.7 billion by 2032.
• Europe is expected to grow the fastest during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

The Global Myocardial Infarction Market Size is expected to reach USD 3.7 billion by 2032, at a CAGR of 6.8% during the forecast period 2022 to 2032.

 

Market Overview

The medical term for a heart attack is myocardial infarction. When the blood supply to the heart muscle is suddenly cut off, which results in tissue damage, a heart attack, a deadly disease, can happen. Typically, one or more coronary arteries are blocked, which is what causes this. Plaque accumulation, which is mostly made up of fat, cholesterol, and cellular waste materials, can cause a blockage to develop. Myocardial infarction symptoms include perspiration, nausea, heartburn, and chest pain or discomfort. Age, cigarette use, high blood pressure, obesity, diabetes, use of illegal drugs, stress, and other risk factors all contribute to the undesired development of fatty deposits (atherosclerosis), which narrow arteries throughout the body and may lead to heart attacks. Treatment for cardiac arrest and the hazards connected to it includes the use of medications such as aspirin, antiplatelet medicines, and stress relievers. The treatment of artery blockages and heart attacks also includes the use of drugs like PTA and stents. By way of an artery in the wrist or projection, a long, thin conduit is sent to the clogged artery. To restore the plasma distribution in the heart muscle, a procedure called a cardiac artery bypass might be performed if necessary.

 

Report Coverage

This research report categorizes the global myocardial infarction market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global myocardial infarction market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global myocardial infarction market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

 

Driving Factors

Increasing product approvals is expected to be a driving factor in the myocardial infarction market. The sector consistently experiences new advancements, which fuel more product launches and market expansion. Additionally, there has been a noteworthy rise in worldwide public efforts and programs to raise awareness of cardiovascular disorders, which is predicted to hasten the rate of expansion of the myocardial infarction market. Moreover, one person in the United States dies from a CVD every 34 seconds, according to figures released by the Centers for Disease Control and Prevention. In addition, 1 in 5 fatalities in the country was predicted to be caused by heart disease in 2020, with an anticipated 697,000 deaths. Moreover, it is anticipated that in the next years, there will be an increase in the number of clinical studies for the treatment of castrate-resistant prostate cancer, which is anticipated to drive the market for myocardial infarction. In addition, a rise in cardiovascular disease cases will be brought on by rising blood pressure, obesity, and smoking rates as well as inactivity. Over the forecast period, the worldwide market for myocardial infarction is anticipated to rise due to the rising prevalence of cardiovascular illnesses.

 

Restraining Factors

The strict regulatory laws and regulations governing the healthcare industry are one of the major factors restraining the growth of the myocardial infarction market. The market's expansion may also be hampered by clinical trials high cost. Further reducing the market's growth is anticipated to be an increase in total healthcare spending.

 

Market Segmentation

• In 2022 the analgesics segment is influencing the market with the largest market share over the forecast period.

On the basis of drug class, the global myocardial infarction market is bifurcated into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, and analgesics. Among these segments, the analgesics segment is dominating the market due to the medication used to treat pain is known as an analgesic. They affect the central and peripheral neural systems differently. A particular family of analgesics known as NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) works by inhibiting COX enzymes to lessen pain by lowering inflammation. NSAIDs may raise your risk of myocardial infarction and stroke, according to the FDA. They are appropriately designated as a result. Both prescription and over-the-counter versions of these medications are offered.

 

• In 2022, the oral segment is dominating the largest market share over the forecast period.

Based on the route of administration, the global myocardial infarction market is segmented into oral and injectable. Among these segments, the oral segment is dominating the market. Myocardial infarction medications can be taken orally or administered intravenously. There would be a significant difference between the number of medications taken orally and those supplied intravenously throughout the anticipated duration.

 

• In 2022, the hospital pharmacies segment is influencing the largest market growth during the forecast period.

Based on the distribution channel, the global myocardial infarction market is classified into different segments such as hospital pharmacies, retail pharmacies, and online pharmacies. Among these segments, the hospital pharmacies segment is expected to influence the market during the forecast period owing to the increased usage of modern technology and expenditures in healthcare infrastructure. However, because of the rising demand from healthcare participants in surgical care, including healthcare professionals, patients, and insurance, online drug shops are anticipated to see the fastest increase throughout the projection period. The rise of this market is also anticipated to be boosted by rising healthcare professionals' demands for patient happiness, affordable treatments, and effective techniques.

 

Regional Segment Analysis of the myocardial infarction market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America leads the market with the largest market share during the forecast period

 

Get more details on this report -

Request Free Sample PDF

North America is dominating the significant market growth during the forecast period. The market expansion in this area is largely driven by the rise in incidences and prevalence of high rates of heart illnesses as well as the rising number of people suffering from obesity. The risk of myocardial infarction is further increased by inactivity, and it is estimated that 30.4% of American adults do not participate in any kind of physical activity. Mexico is anticipated to have a modest growth rate on a national level due to limited government spending on healthcare and a shortage of healthcare professionals. Furthermore, it has low rates of everyday drinking and smoking.

 

Europe is expected to experience high revenue market growth during the forecast period, due to an increase in the number of products being approved by European regulatory bodies to treat cardiac conditions. However, the EU government is taking several steps to improve the healthcare system and support programs that aim to lower the incidence of cardiovascular illnesses.

 

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the global myocardial infarction market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Apotex Inc.
• AstraZeneca
• Bayer AG
• Boehringer-Ingelheim
• Bristol-Myers Squibb Company
• Daiichi Sankyo Co. Ltd.
• Mylan N.V.
• Novartis AG
• Par Pharmaceutical Companies Inc.
• Pfizer Inc.

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In November 2022, Abiomed is a provider of cardiovascular technologies, and Johnson & Johnson has agreed to purchase it for USD 16.6 billion. Abiomed will strengthen Johnson & Johnson MedTech's position as a developing cardiovascular innovator after the transaction is completed and operate as a separate business. This will advance the standard of care for one of the most serious diseases, heart failure, and help patients recover.

 

• In November 2022, it was shown that the Chinese herbal medicine ingredient tongxiluo lowers the risk of mortality following an acute myocardial infarction. A study presented at the American Heart Association in 2022 discovered that the traditional herbal ingredient reduced the chance of cardiac arrest or cerebrovascular attack by 36% compared to placebo medication. This substance has potential as an adjuvant therapy for treating STEMI, especially in poor nations.

 

• In May 2021, Recardio Inc., a clinical-stage life science company that specializes in regenerative therapies for cardiovascular diseases, finished its Phase 2 randomized, double-blind, placebo-controlled, safety, and efficacy study of dutogliptin combined with filgrastim in early recovery post-myocardial infarction.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Myocardial Infarction Market based on the below-mentioned segments:

 

Global Myocardial Infarction Market, By Drug Class

• Antiplatelet Agents
• Glycoprotein IIb/IIIa Inhibitors
• Antithrombotic Agents
• Beta-adrenergic Blockers
• Vasodilators
• Angiotensin-converting Enzyme (ACE) Inhibitors
• Angiotensin-receptor Blockers
• Analgesics

 

Global Myocardial Infarction Market, By Route of Administration

• Oral
• Injectable

 

Global Myocardial Infarction Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 

Myocardial Infarction Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico 
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa